Biological therapy in systemic lupus erythematosus

International Journal of Rheumatology

Volumn 2012, Issue , 2012, Pages

  Postal, Mariana ^a   Costallat, Lilian Tl ^a   Appenzeller, Simone ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; AMG 557; AMG 811; ATACICEPT; B LYMPHOCYTE TOLEROGEN; CD20 ANTIBODY; CD22 ANTIBODY; CELL ANTIBODY; DRUG ANTIBODY; EDRATIDE; EFALIZUMAB; EPRATUZUMAB; IMMUNOLOGIC AGENT; INFLIXIMAB; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 15 ANTIBODY; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B N10; OCRELIZUMAB; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SIFALIMUMAB; TOCILIZUMAB; TORALIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVERSE DRUG REACTION; ANTIBODY DETECTION; ANTIBODY PRODUCTION; B CELL LYMPHOMA; B LYMPHOCYTE; BIOLOGICAL THERAPY; CYTOKINE INHIBITION; CYTOKINE RELEASE; DISCOID LUPUS ERYTHEMATOSUS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFUSION REACTION; LEUKOENCEPHALOPATHY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS INHIBITION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS RASH; T LYMPHOCYTE;

EID: 84858314935     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2012/578641     Document Type: Review

References (93)

1. Rahman A., Isenberg D. A., Systemic lupus erythematosus The New England Journal of Medicine 2008 358 9 929 939 (Pubitemid 351397092)
2. Hahn B. H., Targeted therapies in systemic lupus erythematosus: successes, failures and future Annals of the Rheumatic Diseases 2011 70 supplement 1 i64 i66
3. Human Genome Sciences, Human Genome Sciences and GlaxoSmithKline announce FDA priority review designation for Benlysta (belimumab) as a potential treatment for systemic lupus erythematosus. http://www.hgsi.com/belimumab.html/
4. Haubitz M., New and emerging treatment approaches to lupus Biologics 2010 4 263 271
5. Trager J., Ward M. M., Mortality and causes of death in systemic lupus erythematosus Current Opinion in Rheumatology 2001 13 5 345 351 (Pubitemid 32929862)
6. Anolik J., Sanz I., B cells in human and murine systemic lupus erythematosus Current Opinion in Rheumatology 2004 16 5 505 512 (Pubitemid 39128317)
7. Sabahi R., Anolik J. H., B-cell-targeted therapy for systemic lupus erythematosus Drugs 2006 66 15 1933 1948 (Pubitemid 44771932)
8. Ding C., Foote S., Jones G., B-cell-targeted therapy for systemic lupus erythematosus: an update BioDrugs 2008 22 4 239 249 (Pubitemid 351969831)
9. Murdaca G., Colombo B. M., Puppo F., Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmunity Reviews. In press
10. Roccatello D., Sciascia S., Rossi D., Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy Nephrology Dialysis Transplantation 2011 26 3987 3992
11. FDA Consum,. Rituxan warning, vol. 41, pp.3, 2007
12. Abud-Mendoza C., Moreno-Valdés R., Cuevas-Orta E., Borjas A., Aranda F., Irazoque F., Andrade L., Vigna-Pérez M., Gonzlez-Amaro R., Treating severe systemic lupus erythematosus with rituximab. An open study Reumatologia Clinica 2009 5 4 147 152
13. Leandro M. J., Edwards J. C., Cambridge G., Ehrenstein M. R., Isenberg D. A., An open study of B lymphocyte depletion in systemic lupus erythematosus Arthritis and Rheumatism 2002 46 10 2673 2677 (Pubitemid 36118931)
14. Merrill J. T., Neuwelt C. M., Wallace D. J., Shanahan J. C., Latinis K. M., Oates J. C., Utset T. O., Gordon C., Isenberg D. A., Hsieh H. J., Zhang D., Brunetta P. G., Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Arthritis and Rheumatism 2010 62 1 222 233
15. Clinicaltrials.gov, A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis. (LUNAR) (NCT00282347), August 2011, http://www.clinicaltrials.gov/ct2/show/study/ NCT00282347?term=LUNARrank=1
16. ClinicalTrials.gov., Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus. (BEGIN) (NCT00539838), August 2011, http://www.clinicaltrials.gov/ct2/show/NCT00539838?term=Ocrelizumabrank= 10
17. ClinicalTrials.gov, A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) (NCT00626197). August 2011, http://www.clinicaltrials.gov/ct2/show/NCT00539838?term=Ocrelizumabrank=10
18. Petri M. A., Hobbs K., Gordon C., Randomized controlled trials of epratuzumab (anti-CD-22MAB targeting B cells) reveal clinically meaningful improvements in patients with moderate and severe SLE flares Annals of the Rheumatic Diseases 2008 67 supplement 2 53
19. ClinicalTrials.gov, Study of epratuzumab in serologically-positive systemic lupus erythematosus patients with active disease (NCT00624351). August 2011, http://www.clinicaltrials.gov/ct2/show/NCT00624351?term=NCT00624351rank=1
20. ClinicalTrials.gov, Open-label study of epratuzumab in serologically-positive systemic lupus erythematosus patients with active disease (NCT00660881). http://www.clinicaltrials.gov/ct2/show/NCT00660881?term= NCT00660881rank=1
21. Cardiel M. H., Tumlin J. A., Furie R. A., Wallace D. J., Joh T., Linnik M. D., Abeles M., Aelion J., Appel G. B., Aranow C., Ballou S., Becker M. A., Belmont H. M., Boling E. P., Bombardieri S., Brodeur J., Buyon J., Condemi J. J., Cronin M. E., Cush J. J., DeHoratius R., Desir D., Donohue J., Edwards M., El-Shahawy M. A., Emery P., Ensworth S., Espinoza L. R., Fondal M., Fortin P., Geppert T., Gilkeson G. S., Ginzler E., Gorevic P., Granda J., Grossman J., Hiepe F., Howard P., Hura C. E., Jaffer A., Jakes J., Kalden J. R., Kammer G. M., Kaplan M. J., Kaplan S., Katz R., Kennedy A., Kenney H. M., Khamashta M., Kivitz A. J., Kovacs C., Krishnan M., Kurtzman N. A., Liebling M., Lourie S. H., Loveless J., Manion C. V., Manzi S., Martin K., McKay J., Mease P. J., Merrill J. T., Moreland L. W., Moritz C., Neuwelt C. M., Petri M., Pogue B. C., Quinet R. J., Ramsey-Goldman R., Roth A., Rothfield N., Scarpa N., Schneider M., Shergy W. J., Sherrer Y., Sibilia J., Sisay M., Smith D., Spinowitz B., Spira M., Stevens M. P., Sturfelt G., Surbeck W., Tindall E. A., Torres A., Van Vollenhoven R., Vijayan A., Vilardell-Tarres M., Weaver C., Williams G. W., Zummer M., Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial Arthritis and Rheumatism 2008 58 8 2470 2480
22. ClinicalTrials.gov, A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus (PRELUDE) (NCT00203151). August 2011, http://www.clinicaltrials.gov/ct2/show/NCT00203151?term= Edratiderank=1
23. Wallace D. J., Stohl W., Furie R. A., Lisse J. R., McKay J. D., Merrill J. T., Petri M. A., Ginzler E. M., Chatham W. W., McCune W. J., Fernandez V., Chevrier M. R., Zhong Z. J., Freimuth W. W., A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus Arthritis Care and Research 2009 61 9 1168 1178
24. Dall'Era M., Chakravarty E., Wallace D., Genovese M., Weisman M., Kavanaugh A., Kalunian K., Dhar P., Vincent E., Pena-Rossi C., Wofsy D., Alum N., Dubois A., Kinnman N., Picard M., Bortolotti A., O'Grady L., Hill J., Nestorov I., Salmon E., Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial Arthritis and Rheumatism 2007 56 12 4142 4150 (Pubitemid 350262342)
25. ClinicalTrials.gov, Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis (ACCESS) (NCT00774852). August 2011, http://www. clinicaltrials.gov/ct2/show/NCT00774852?term=abatacept+slerank=4
26. ClinicalTrials.gov, Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis (NCT00430677). http://www.clinicaltrials.gov/ct2/show/NCT00430677? term=abatacept+slerank=2
27. Kalunian K. C., Davis J. C., Merrill J. T., Totoritis M. C., Wofsy D., Treatment of Systemic Lupus Erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial Arthritis and Rheumatism 2002 46 12 3251 3258 (Pubitemid 35453534)
28. Usmani N., Goodfield M., Efalizumab in the treatment of discoid lupus erythematosus Archives of Dermatology 2007 143 7 873 877 (Pubitemid 47076485)
29. ClinicalTrials, A Study of AMG 557 in Adults With Systemic Lupus Erythematosus. (NCT00774943), October 2011, http://www.clinicaltrials.gov/ct2/ show/NCT00774943?term=AMG557rank=2
30. Fernandez D., Bonilla E., Mirza N., Niland B., Perl A., Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus Arthritis and Rheumatism 2006 54 9 2983 2988 (Pubitemid 44497779)
31. Aringer M., Houssiau F., Gordon C., Graninger W. B., Voll R. E., Rath E., Steiner G., Smolen J. S., Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients Rheumatology 2009 48 11 1451 1454
32. Wallace D. J., Petri M. A., Olsen M., MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus Arthritis Rheumatism 2007 56 526 527
33. ClinicalTrials.gov., A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus. (ROSE)(NCT00962832), August 2011, http://www.clinicaltrials.gov/ ct2/show/NCT00962832?term=Rontalizumabrank=1
34. ClinicalTrials.gov., Safety Study of AMG 811 in Subjects with Systemic Lupus Erythematosus With and Without Glomerulonephritis. (NCT00818948), August 2011, http://www.clinicaltrials.gov/ct2/show/NCT00818948?term=AMG+811rank=2
35. Ostendorf B., Iking-Konert C., Kurz K., Jung G., Sander O., Schneider M., Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis Annals of the Rheumatic Diseases 2005 64 4 630 633 (Pubitemid 40469097)
36. Illei G. G., Shirota Y., Yarboro C. H., Daruwalla J., Tackey E., Takada K., Fleisher T., Balow J. E., Lipsky P. E., Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study Arthritis and Rheumatism 2010 62 2 542 552
37. Llorente L., Richaud-Patin Y., Garca-Padilla C., Clinical and biologic effects of antiinterleukin-10 monoclonal antibody administration in systemic lupus erythematosus Arthritis Rheumatism 2000 43 1790 1800
38. Perosa F., Favoino E., Caragnano M. A., Prete M., Dammacco F., CD20: a target antigen for immunotherapy of autoimmune diseases Autoimmunity Reviews 2005 4 8 526 531 (Pubitemid 41415764)
39. Grillo-Lpez A. J., White C. A., Dallaire B. K., Varns C. L., Shen C. D., Wei A., Leonard J. E., McClure A., Weaver R., Cairelli S., Rosenberg J., Rituximab: the first monoclonal antibody approved for the treatment of lymphoma Current Pharmaceutical Biotechnology 2000 1 1 1 9
40. Garca-Carrasco M., Jiménez-Hernndez M., Escrcega R. O., Mendoza-Pinto C., Galarza-Maldonado C., Sandoval-Cruz M., Zamudio-Huerta L., Lpez-Colombo A., Cervera R., Use of rituximab in patients with systemic lupus erythematosus: an update Autoimmunity Reviews 2009 8 4 343 348
41. Galarza-Maldonado C., Kourilovitch M. R., Molineros J. E., Cardiel M. H., Zurita L., Soroka N. F., Yagur V. Y., Doukh N., Cervera R., The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus Autoimmunity Reviews 2010 10 2 108 111
42. Lu T. Y. T., Ng K. P., Cambridge G., Leandro M. J., Edwards J. C. W., Ehrenstein M., Isenberg D. A., A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: the first fifty patients Arthritis Care and Research 2009 61 4 482 487
43. Pinto L. F., Velsquez C. J., Prieto C., Mestra L., Forero E., Mrquez J. D., Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus Lupus 2011 20 11 1219 1226
44. Terrier B., Amoura Z., Ravaud P., Hachulla E., Jouenne R., Combe B., Bonnet C., Cacoub P., Cantagrel A., De Bandt M., Fain O., Fautrel B., Gaudin P., Godeau B., Harlé J. R., Hot A., Kahn J. E., Lambotte O., Larroche C., Léone J., Meyer O., Pallot-Prades B., Pertuiset E., Quartier P., Schaerverbeke T., Sibilia J., Somogyi A., Soubrier M., Vignon E., Bader-Meunier B., Mariette X., Gottenberg J. E., Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry Arthritis and Rheumatism 2010 62 8 2458 2466
45. Reynolds J. A., Toescu V., Yee C. S., Prabu A., Situnayake D., Gordon C., Effects of rituximab on resistant SLE disease including lung involvement Lupus 2009 18 1 67 73
46. Turner-Stokes T., Lu T. Y., Ehrenstein M. R., The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation Rheumatology 2011 50 1401 1408
47. Anolik J. H., Aringer M., New treatments for SLE: cell-depleting and anti-cytokine therapies Best Practice and Research 2005 19 5 859 878 (Pubitemid 41258587)
48. Lateef A., Petri M., Biologics in the treatment of systemic lupus erythematosus Current Opinion in Rheumatology 2010 22 5 504 509
49. Wallace D. J., Hobbs K., Houssiau F., Randomized controlled trials of epratuzumab (anti-CD-22MAB targeting B cells) reveal clinically meaningful reductions in corticosteroid use with favorable safety profile in moderate and severe flaring SLE patients Annals of the Rheumatic Diseases 2008 67 supplement 2 212
50. Yildirim-Toruner C., Diamond B., Current and novel therapeutics in the treatment of systemic lupus erythematosus Journal of Allergy and Clinical Immunology 2011 127 2 303 312
51. ClinicalTrials.gov, Study of LJP 394 in Lupus Patients with History of Renal Disease (ASPEN) (NCT00089804). August 2011, http://www.clinicaltrials.gov/ ct2/show/NCT00089804?term= Study+of+LJP+394+in+lupus+patients+with+history+of+renal+disease+28ASPEN29.rank= 1
52. ClinicalTrials.gov, A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) (BLISS-76) (NCT00410384). August 2011, http://www. clinicaltrials.gov/ct2/show/study/NCT00410384?term=BLISS-76rank=1
53. ClinicalTrials.gov, The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis. (NCT00573157), August 2011, http://www.clinicaltrials.gov/ct2/show/NCT00573157?term= The+efficacy+and+safety+of+atacicept+in+combination+with+mycophenolate+mofetilr ank=1
54. Gayed M., Gordon C., Novel treatments for systemic lupus erythematosus Current Opinion in Investigational Drugs 2010 11 11 1256 1264
55. ClinicalTrials.gov, Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus (April SLE) (NCT00624338). http://www.clinicaltrials.gov/ct2/show/ NCT00624338?term=April+SLErank=1
56. Schiffer L., Sinha J., Wang X., Huang W., Von Gonsdorff G., Schiffer M., Madaio M. P., Davidson A., Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition Journal of Immunology 2003 171 1 489 497 (Pubitemid 36745324)
57. Navarra S. V., Immune therapy of lupus: what is on the horizon? Nephrology Dialysis Transplantation 2006 21 3 579 581 (Pubitemid 43372901)
58. Merrill J. T., Burgos-Vargas R., Westhovens R., Chalmers A., D'Cruz D., Wallace D. J., Bae S. C., Sigal L., Becker J. C., Kelly S., Raghupathi K., Li T., Peng Y., Kinaszczuk M., Nash P., The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial Arthritis and Rheumatism 2010 62 10 3077 3087
59. Akkerman A., Huang W., Wang X., Ramanujam M., Schiffer L., Madaio M., Factor S. M., Davidson A., CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice Autoimmunity 2004 37 6-7 445 451 (Pubitemid 40123413)
60. Wang X., Huang W., Schiffer L. E., Mihara M., Akkerman A., Hiromatsu K., Davidson A., Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus Arthritis and Rheumatism 2003 48 2 495 506 (Pubitemid 36278019)
61. Boumpas D. T., Furie R., Manzi S., Illei G. G., Wallace D. J., Balow J. E., Vaishnaw A., A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis Arthritis and Rheumatism 2003 48 3 719 727 (Pubitemid 36302008)
62. Fernandez D. R., Telarico T., Bonilla E., Li Q., Banerjee S., Middleton F. A., Phillips P. E., Crow M. K., Oess S., Muller-Esterl W., Perl A., Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation Journal of Immunology 2009 182 4 2063 2073
63. Perl A., Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment Autoimmunity 2010 43 1 32 47
64. Warner L. M., Adams L. M., Sehgal S. N., Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus Arthritis and Rheumatism 1994 37 2 289 297 (Pubitemid 24065505)
65. La Cava A., Anticytokine therapies in systemic lupus erythematosus Immunotherapy 2010 2 4 575 582
66. Jacob C. O., McDevitt H. O., Tumour necrosis factor- in murine autoimmune 'lupus' nephritis Nature 1988 331 6154 356 358 (Pubitemid 18042493)
67. Brennan D. C., Yui M. A., Wuthrich R. P., Kelley V. E., Tumor necrosis factor and IL-1 in New Zealand black/white mice. Enhanced gene expression and acceleration of renal injury Journal of Immunology 1989 143 11 3470 3475 (Pubitemid 20007007)
68. Edwards C. K., Zhou T., Zhang J., Baker T. J., De M., Long R. E., Borcherding D. R., Bowlin T. L., Bluethmann H., Mountz J. D., Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF- Journal of Immunology 1996 157 4 1758 1772 (Pubitemid 126449121)
69. Tracey D., Klareskog L., Sasso E. H., Salfeld J. G., Tak P. P., Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacology and Therapeutics 2008 117 2 244 279
70. Hochberg M. C., Lebwohl M. G., Plevy S. E., Hobbs K. F., Yocum D. E., The benefit/risk profile of TNF-blocking agents: findings of a consensus panel Seminars in Arthritis and Rheumatism 2005 34 6 819 836 (Pubitemid 40740207)
71. Rosenblum H., Amital H., Anti-TNF therapy: safety aspects of taking the risk Autoimmunity Reviews 2011 10 9 563 568
72. Bender N. K., Heilig C. E., Drll B., Wohlgemuth J., Armbruster F. P., Heilig B., Immunogenicity, efficacy and adverse events of adalimumab in RA patients Rheumatology International 2007 27 3 269 274 (Pubitemid 46088257)
73. Braun D., Geraldes P., Demengeot J., Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice Journal of Autoimmunity 2003 20 1 15 25 (Pubitemid 36207624)
74. Santiago-Raber M. L., Baccala R., Haraldsson K. M., Choubey D., Stewart T. A., Kono D. H., Theofilopoulos A. N., Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice Journal of Experimental Medicine 2003 197 6 777 788 (Pubitemid 36350872)
75. Balomenos D., Rumold R., Theofilopoulos A. N., Interferon- is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice Journal of Clinical Investigation 1998 101 2 364 371 (Pubitemid 28067333)
76. Jacob C. O., van der Meide P. H., McDevitt H. O., In vivo treatment of (NZB x NZW)F1 lupus-like nephritis with monoclonal antibody to interferon Journal of Experimental Medicine 1987 166 3 798 803 (Pubitemid 18013554)
77. Lawson B. R., Prud'homme G. J., Chang Y., Gardner H. A., Kuan J., Kono D. H., Theofilopoulos A. N., Treatment of murine lupus with cDNA encoding IFN- R/Fc Journal of Clinical Investigation 2000 106 2 207 215 (Pubitemid 30483124)
78. Nicoletti F., Di Marco R., Zaccone P., Xiang M., Magro G., Grasso S., Morrone S., Santoni A., Shoenfeld Y., Garotta G., Meroni P., Dichotomic effects of IFN- on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice European Journal of Immunology 2000 30 2 438 447 (Pubitemid 30098836)
79. Koutouzov S., Mathian A., Dalloul A., Type-I interferons and systemic lupus erythematosus Autoimmunity Reviews 2006 5 8 554 562 (Pubitemid 44508854)
80. Rnnblom L., Eloranta M. L., Alm G. V., The type I interferon system in systemic lupus erythematosus Arthritis and Rheumatism 2006 54 2 408 420 (Pubitemid 43228615)
81. Baechler E. C., Batliwalla F. M., Karypis G., Gaffney P. M., Ortmann W. A., Espe K. J., Shark K. B., Grande W. J., Hughes K. M., Kapur V., Gregersen P. K., Behrens T. W., Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus Proceedings of the National Academy of Sciences of the United States of America 2003 100 5 2610 2615 (Pubitemid 36297546)
82. Suzuki H., Takemura H., Kashiwagi H., Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus: enhanced production by monocytes and correlation with disease activity Arthritis and Rheumatism 1995 38 8 1055 1059
83. Sturfelt G., Roux-Lombard P., Wollheim F. A., Dayer J. M., Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus British Journal of Rheumatology 1997 36 12 1283 1289
84. Finck B. K., Chan B., Wofsy D., Interleukin 6 promotes murine lupus in NZB/NZW F1 mice Journal of Clinical Investigation 1994 94 2 585 591 (Pubitemid 24250987)
85. Tak P. P., Kalden J. R., Advances in rheumatology: new targeted therapeutics Arthritis Research and Therapy 2011 13 supplement 1 S1 S5
86. Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., Howard M., Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice Journal of Experimental Medicine 1994 179 1 305 310 (Pubitemid 24012996)
87. Aringer M., Stummvoll G. H., Steiner G., Kller M., Steiner C. W., Hfler E., Hiesberger H., Smolen J. S., Graninger W. B., Serum interleukin-15 is elevated in systemic lupus erythematosus Rheumatology 2001 40 8 876 881
88. Park M. C., Park Y. B., Lee S. K., Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus Clinical Rheumatology 2004 23 3 225 229 (Pubitemid 38812201)
89. Ogata A., Kitano M., Fukamizu M., Hamano T., Sano H., Increased serum interleukin-18 in a patient with systemic lupus erythematosus and T-cell large granular lymphocytic leukemia Modern Rheumatology 2004 14 3 267 270 (Pubitemid 39206677)
90. Favilli F., Anzilotti C., Martinelli L., Quattroni P., De Martino S., Pratesi F., Neumann D., Beermann S., Novick D., Dinarello C. A., Boraschi D., Migliorini P., IL-18 activity in systemic lupus erythematosus Annals of the New York Academy of Sciences 2009 1173 301 309
91. Boss P., Neumann D., Del Giudice E., Ciaramella A., Gloaguen I., Fantuzzi G., Dinarello C. A., Di Carlo E., Musiani P., Meroni P. L., Caselli G., Ruggiero P., Boraschi D., IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease Proceedings of the National Academy of Sciences of the United States of America 2003 100 2 14181 14186 (Pubitemid 37499211)
92. Bao L., Quigg R. J., Complement in lupus nephritis: the good, the bad, and the unknown Seminars in Nephrology 2007 27 1 69 80
93. Dmytrijuk A., Robie-Suh K., Cohen M. H., Rieves D., Weiss K., Pazdur R., FDA report: Eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria Oncologist 2008 13 9 993 1000